miRagen Therapeutics Achieves First Milestone in Strategic Alliance With Servier
5/23/2013 10:59:42 AM
More...
|
miRagen Therapeutics Exclusively Licenses Intellectual Property From the University of Glasgow for microRNA-145 Targeting in the Treatment of Pulmonary Arterial Hypertension
3/5/2013 9:44:01 AM
More...
|
Santaris Pharma A/S and miRagen Therapeutics Expand Worldwide Strategic Alliance to Discover and Develop LNA-Drugs Against Disease Causing Micrornas
1/8/2013 9:56:12 AM
More...
|
miRagen Therapeutics Named to FierceBiotech’s 2012 Fierce 15 List of Most Promising Private Biotechnology Companies
9/19/2012 9:52:39 AM
More...
|
miRagen Therapeutics Announces the Publication of Compelling Data Suggesting the MIRG-9103 Program May Have Utility in Treating Multiple Disorders Associated with Metabolic Syndrome
4/26/2012 10:55:35 AM
More...
|
miRagen Therapeutics Expands Executive Team Adding Drug Development Veteran
4/24/2012 10:25:39 AM
More...
|
miRagen Therapeutics Secures $20 Million Series B Financing
4/24/2012 7:08:03 AM
More...
|
Silence Therapeutics plc Signs Collaboration with miRagen Therapeutics to Evaluate Delivery of Novel microRNA-based Therapeutics
1/9/2012 10:34:16 AM
More...
|
miRagen Therapeutics to Present at Biotech Showcase 2012
1/6/2012 6:36:54 AM
More...
|
miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart
11/4/2011 7:13:44 AM
More...
|
|